Unity Biotechnology is harnessing pathways of aging biology to develop new medicines, focusing on retinal diseases. Self-described as at the forefront of developing a new class of therapeutics that aim to restore diseased tissue to a healthier state.

Unity Biotechnology

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Unity Biotechnology, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 1, 2024 7:24 PM	23462469
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Oct 1, 2024 9:02 PM	b2be6ba5
company summary	general
signals	general	Oct 1, 2024 7:24 PM	084d2445
crunchbase trigger	general	Nov 27, 2024 12:50 PM	1ef29396
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 1, 2024 7:24 PM	1e741861
news basic	general	Oct 1, 2024 7:24 PM	8edb7c18
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:UNITYBIOTECHNOLOGY

Unity Biotechnology

Last Close

1.16

22/11 21:00

Market Cap

24.34M

Beta: -

Volume Today

56.99K

Avg: -